Replies to post #683723 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Excellent analysis JFR. It would be UK's feather in the cap to have
introduced the first cancer vaccine well before the January 28, 2025
elections.

[NotSure2]

StonkMaster: Thanks for posting these timelines.

Disregard those saying "you are wrong".

How could you be wrong, you are only putting timelines, not "predictions" (which is usefull to all of us).

In order to remove these bad replies, you should add a timeline that says:

1 to 5 days: Approval imminent.

(this will satisfies the idiots/crybaby. They keep being off in 99% of their predictions, and never learn. Having this timeline will trick them easily)

[StonkMaster]

How am I wrong? I'm literally just listing a bunch of dates in line with what we've been told by the company and historic metrics from the MHRA. They requested the 150 day pathway. That doesn't include a RFI, which they themselves said is very possible. It's crazy that people view 150 days as too long, when we're only 40-50 days away and history says that would very much be considered a quicker than average assessment.

If you think it'll be earlier, that's great! My posts are simply a REALISTIC reference tool. I'd love for it to be quicker than 150 days, trust me. But nobody has any real evidence that this could set a new standard for assessment length. I don't want to be giving false hope like so many on this board are so good at doing. A bunch of the same crowd said we would have approval within 30-80 days from submission. Shocker, that turned out to be wrong, again. My posts could list every single possible approval date, would that make you happy? Fact is, PERSONALLY, I believe a 210 day assessment is more likely than a 120 day (next week) assessment. That's my opinion. You can have yours.

[Hbpainter]

I think you'll find in UK politics, if a political party tries to take credit for an advancement in the treatment of cancer, literally no one will take them seriously. If anything it could backfire. I know politics everywhere has lost credibility but it won't wash in the UK, IMO.

[Nemesis18]

I think that the Dendritic Cell approach when used as an adjuvant, or piggy back treatment has a real chance of making inroads into the treatment of GBM4 over the next 5-10 years.

Whether NWBO’s licensed Variant is the one to lead that vanguard remains to be seen shortly.
But if it should fall at this first significant Regulatory Hurdle, Advent is perfectly placed now to pick up the third party work that will fill the void left in this field.
In this regard, LP has selfishly covered her bases very well, and should be respected for that ruthless self-preservation business instinct !

Don’t blame the Player, blame the game.

In terms of DCVAX-L replacing Chemotherapy as the front line treatment, off the back of one liquidised P3 trial, there is zero chance of that happening.
But as other DC variants start coming through over the years, I think that this approach will certainly gain some Temozolomide etc ( which is a fecking brutal, scorched-earth treatment )

[JFR161162]

I estimate a 30% chance of MAA approval in April and a 70% chance in May due to:

1- Political support from both major parties in the UK.

2- The UK's efforts to attract biopharmaceutical companies and investment for clinical trials following its departure from the EU in 2020.
UK has new programs for accelerated approvals & trials.
They can’t have delays at this point of time.
A decision is expected at the latest by the end of May, within 150 days.